Development and in vitro evaluation of an oral SEDDS for desmopressin

References

• Bandivadekar M, Pancholi S, Kaul-Ghanekar R, et al. (2013). Single non-ionic surfactant based self-nanoemulsifying drug delivery systems: formulation, characterization, cytotoxicity and permeability enhancement study. Drug Dev Ind Pharm 39:696–703
   PubMed Web of Science ®Google Scholar
• Belhadj Z, Zhang S, Zhang W, Junlin W. (2013). Formulation development and bioavailability evaluation of a Self-nanoemulsifying Drug Delivery System (SNEDDS) of atorvastatin calcium. Int J Pharm 29:2051–5782
   Google Scholar
• Choi SH, Park TG. (2000). Hydrophobic ion pair formation between leuprolide and sodium oleate for sustained release from biodegradable polymeric microspheres. Int J Pharm 203:193–202
   PubMed Web of Science ®Google Scholar
• Christiansen ML, Holm R, Kristensen J, et al. (2014). Cinnarizine food-effects in beagle dogs can be avoided by administration in a Self Nano Emulsifying Drug Delivery System (SNEDDS). Eur J Pharm Sci 57:164–72
   PubMed Web of Science ®Google Scholar
• Christophersen PC, Zhang L, Müllertz A, et al. (2014). Solid lipid particles for oral delivery of peptide and protein drugs II–the digestion of trilaurin protects desmopressin from proteolytic degradation. Pharm Res 31:2420–8
   PubMed Web of Science ®Google Scholar
• Fatouros DG, Deen GR, Arleth L, et al. (2007). Structural development of self nano emulsifying drug delivery systems (SNEDDS) during in vitro lipid digestion monitored by small-angle X-ray scattering. Pharm Res 24:1844–53
   PubMed Web of Science ®Google Scholar
• Fosgerau K, Hoffmann T. (2015). Peptide therapeutics: current status and future directions. Drug Discov Today 20:122–8
   PubMed Web of Science ®Google Scholar
• Fredholt K, Østergaard J, Savolainen J, Friis GJ. (1999). α-Chymotrypsin-catalyzed degradation of desmopressin (dDAVP): influence of pH, concentration and various cyclodextrins. Int J Pharm 178:223–9
   PubMed Web of Science ®Google Scholar
• Friedl H, Dünnhaupt S, Hintzen F, et al. (2013). Development and evaluation of a novel mucus diffusion test system approved by self‐nanoemulsifying drug delivery systems. J Pharm Sci 102:4406–13
   PubMed Web of Science ®Google Scholar
• Hintzen F, Perera G, Hauptstein S, et al. (2014). In vivo evaluation of an oral self-microemulsifying drug delivery system (SMEDDS) for leuprorelin. Int J Pharm 472:20–6
   PubMed Web of Science ®Google Scholar
• Ilan E, Amselem S, Weisspapir M, et al. (1996). Improved oral delivery of desmopressin via a novel vehicle: mucoadhesive submicron emulsion. Pharm Res 13:1083–7
   PubMed Web of Science ®Google Scholar
• Jannin V, Chevrier S, Michenaud M, et al. (2015). Development of self emulsifying lipid formulations of BCS class II drugs with low to medium lipophilicity. Int J Pharm 495:385–92
   PubMed Web of Science ®Google Scholar
• Kahns AH, Buur A, Bundgaard H. (1993). Prodrugs of peptides. 18. Synthesis and evaluation of various esters of desmopressin (dDAVP). Pharm Res 10:68–74
   PubMed Web of Science ®Google Scholar
• Karamanidou T, Karidi K, Bourganis V, et al. (2015). Effective incorporation of insulin in mucus permeating self-nanoemulsifying drug delivery systems. Eur J Pharm Biopharm 97:223--9
   PubMed Web of Science ®Google Scholar
• Leonaviciute G, Bernkop-Schnürch A. (2015). Self-emulsifying drug delivery systems in oral (poly) peptide drug delivery. Expert Opin Drug Deliv 12:1703–16
   PubMed Web of Science ®Google Scholar
• Mahjub R, Dorkoosh FA, Rafiee-Tehrani M, Bernkop Schnürch A. (2015). Oral self-nanoemulsifying peptide drug delivery systems: impact of lipase on drug release. J Microencapsul 32:401–7
   PubMed Web of Science ®Google Scholar
• Matsui K, Kimura T, Ota K, et al. (1985). Resistance of 1-deamino-(8-D-arginine)-vasopressin to in vitro degradation as compared with arginine vasopressin. Endocrinol Jpn 32:547–57
   PubMedGoogle Scholar
• Meyer JD, Manning MC. (1998). Hydrophobic ion pairing: altering the solubility properties of biomolecules. Pharm Res 15:188–93
   PubMed Web of Science ®Google Scholar
• Müllertz A, Ogbonna A, Ren S, Rades T. (2010). New perspectives on lipid and surfactant based drug delivery systems for oral delivery of poorly soluble drugs. J Pharm Pharmacol 62:1622–36
   PubMed Web of Science ®Google Scholar
• Palamakula A, Khan MA. (2004). Evaluation of cytotoxicity of oils used in coenzyme Q10 Self-emulsifying Drug Delivery Systems (SEDDS). Int J Pharm 273:63–73
   PubMed Web of Science ®Google Scholar
• Partenhauser A, Laffleur F, Rohrer J, Bernkop-Schnürch A. (2015). Thiolated silicone oil: synthesis, gelling and mucoadhesive properties. Acta Biomater 16:169–77
   PubMed Web of Science ®Google Scholar
• Pouton CW. (2006). Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci 29:278–87
   PubMed Web of Science ®Google Scholar
• Pouton CW, Porter CJH. (2008). Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies. Adv Drug Deliv Rev 60:625–37
   PubMed Web of Science ®Google Scholar
• Rao SVR, Shao J. (2008). Self-nanoemulsifying drug delivery systems (SNEDDS) for oral delivery of protein drugs: I. Formulation development. Int J Pharm 362:2–9
   PubMed Web of Science ®Google Scholar
• Schmitz T, Huck CW, Bernkop-Schnürch A. (2006). Characterisation of the thiol-disulphide chemistry of desmopressin by LC, mu-LC, LC-ESI-MS and Maldi-Tof. Amino Acids 30:35–42
   PubMed Web of Science ®Google Scholar
• Shen H, Zhong M. (2006). Preparation and evaluation of self-microemulsifying drug delivery systems (SMEDDS) containing atorvastatin. J Pharm Pharmacol 58:1183–91
   PubMed Web of Science ®Google Scholar
• Shen WC. (2003). Oral peptide and protein delivery: unfulfilled promises? Drug Discov Today 8:607–8
   PubMed Web of Science ®Google Scholar
• Thomas N, Müllertz A, Graf A, Rades T. (2012). Influence of lipid composition and drug load on the in vitro performance of self‐nanoemulsifying drug delivery systems. J Pharm Sci 101:1721–31
   PubMed Web of Science ®Google Scholar
• Wang J, Shen D, Shen WC. (1999). Preparation, purification, and characterization of a reversibly lipidized desmopressin with potentiated anti-diuretic activity. Pharm Res 16:1674–9
   PubMed Web of Science ®Google Scholar
• Wang J, Wu D, Shen WC. (2002). Structure-activity relationship of reversibly lipidized peptides: studies of fatty acid-desmopressin conjugates. Pharm Res 19:609–14
   PubMed Web of Science ®Google Scholar
• Wang J, Yadav V, Smart AL, et al. (2015). Toward oral delivery of biopharmaceuticals: an assessment of the gastrointestinal stability of 17 peptide drugs. Mol Pharm 12:966–73
   PubMed Web of Science ®Google Scholar
• Zhao FK, Chuang LF, Israel M, Chuang RY. (1989). Cremophor EL, a widely used parenteral vehicle, is a potent inhibitor of protein kinase C. Biochem Biophys Res Commun 159:1359–67
   PubMed Web of Science ®Google Scholar
• Zupančič O, Partenhauser A, Lam HT, et al. (2016). Development and in vitro characterisation of an oral self-emulsifying delivery system for daptomycin. Eur J Pharm Sci 81:129--36
   PubMed Web of Science ®Google Scholar